

Notice to Extraordinary General Meeting – Section B: SHAREHOLDERS’ RIGHT TO REQUEST INFORMATION.

Question 1: What is the reason behind performing a rights issue at this point in time, in light of the issues made in 2020 that would reportedly cover the company's costs until 2023?

- The purpose of the directed issue is to secure financing for the continued transformation of BioInvent and expansion of our clinical programs, thereby creating even better conditions for value-creating development of our project portfolio, the company's most important asset. Investors in the directed share issue are a number of international and Swedish investors, including Redmile, Invus, HBM Healthcare Investments, Fourth Swedish National Pension Fund, Swedbank Robur Fonder and Van Herk Investments.

Furthermore, a strengthened financial position will contribute to greater strategic stability and increased strength in negotiating with potential partners.

Question 2: How will you spend the money?

- The net proceeds from the Directed Issue are mainly intended for:
- (i) preparations towards a pivotal clinical trial with the aim of receiving an accelerated regulatory pathway for BI-1206 for the treatment of Non-Hodgkin’s Lymphoma assuming continued generation of positive data;
 - (ii) progressing the clinical development of BI-1206 in its Phase I/II trial for the treatment of advanced solid tumors in combination with Keytruda® (pembrolizumab). Assuming positive clinical data, the net proceeds may be used to broaden the clinical studies;
 - (iii) progressing the clinical development of BI-1808, as monotherapy and in combination with Keytruda® (pembrolizumab), for the treatment of solid tumors and cutaneous T-cell lymphoma (CTCL). Assuming positive clinical data, the net proceeds may be used to broaden the clinical studies;
 - (iv) developing BT-001, in partnership with Transgene, for the treatment of solid cancers. Assuming positive clinical data, the net proceeds may be used to broaden clinical studies;
 - (v) advancing BI-1607 into clinical development for the treatment of solid cancers; and
 - (vi) continued development of the Company’s prioritized preclinical projects with the aim to generate additional clinical programs.

Moreover, a strengthened financial position enables increased strategic flexibility and improved ability to negotiate with potential partners.

Question 3: Do you not foresee that there will be any major deal before the end of 2023?

- In November 2020, it was announced that BioInvent out-licensed the anti-FcγRIIB antibody BI-1206 to CASI Pharmaceuticals for the Chinese region and that BioInvent initially received USD 12 million, in a combination of cash and equity, and is entitled to receive up to USD 83 million in milestone payments, plus incremental royalties. Business development is an ongoing prioritized activity in the operations, and it is BioInvent's ambition to continue licensing projects to partners for further development, at times deemed appropriate and beneficial. However, it is not possible to make any further statements on the timing of further such agreements.
